NDAORALFOR SUSPENSION
Approved
Sep 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLAPEN-W (cyclacillin) is an oral suspension antibiotic approved in 1979 for bacterial infections. It belongs to the penicillin class and is administered orally, making it suitable for outpatient treatment. The drug targets susceptible gram-positive and gram-negative bacteria through inhibition of bacterial cell wall synthesis.
LOE Approaching
With LOE approaching and low competitive pressure (30%), this product faces declining market relevance and likely reduced commercial team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYCLAPEN-W generates zero linked job opportunities, reflecting its mature LOE status and minimal commercial momentum. Roles supporting this product are primarily operational and compliance-focused rather than growth-oriented.
Regulatory AffairsQuality Assurance
Worked on CYCLAPEN-W at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.